Global Chemotherapy-induced Nausea and Vomiting Drugs Market Overview:
Global Chemotherapy-induced Nausea and Vomiting Drugs Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Chemotherapy-induced Nausea and Vomiting Drugs Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Chemotherapy-induced Nausea and Vomiting Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Chemotherapy-induced Nausea and Vomiting Drugs Market:
The Chemotherapy-induced Nausea and Vomiting Drugs Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Chemotherapy-induced Nausea and Vomiting Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Chemotherapy-induced Nausea and Vomiting Drugs Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Chemotherapy-induced Nausea and Vomiting Drugs market has been segmented into:
Serotonin Receptor Antagonist
Neurokinin NK1 Receptor Antagonist
Dopamine Antagonist
Benzodiazepine
Other Segments).
By Application, Chemotherapy-induced Nausea and Vomiting Drugs market has been segmented into:
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Chemotherapy-induced Nausea and Vomiting Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Chemotherapy-induced Nausea and Vomiting Drugs market.
Top Key Players Covered in Chemotherapy-induced Nausea and Vomiting Drugs market are:
Acacia Pharma Group Plc
Aphios Corporation
Baxter International Inc.
Dr. Reddy's Laboratories Ltd.
Eisai Co. Ltd.
Especificos Stendhal S.A. DE C.V.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Helsinn Healthcare SA
Heron Therapeutics Inc.
Kyowa Hakko Kirin Co. Ltd.
Lee's Pharmaceutical Holdings Ltd.
Merck & Co. Inc.
Midatech Pharma PLC
Mundipharma Pte. Ltd.
Mylan N.V.
Ono Pharmaceutical Co. Ltd.
Opko Health Inc.
Orchid Chemicals & Pharmaceuticals Ltd
Otsuka Pharmaceutical Co. Ltd.
Purdue Pharma LP
Sandoz International GmbH
SciClone Pharmaceuticals Inc.
Shin Nippon Biomedical Laboratories Ltd. (SNBL)
Solasia Pharma K.K.
Specialised Therapeutics Asia Pte Ltd
Sun Pharmaceutical Industries Ltd.
Taiho Pharmaceutical Co. Ltd.
Tesaro Inc.
Teva Pharmaceutical Industries Ltd.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Chemotherapy-induced Nausea and Vomiting Drugs Market Type
4.1 Chemotherapy-induced Nausea and Vomiting Drugs Market Snapshot and Growth Engine
4.2 Chemotherapy-induced Nausea and Vomiting Drugs Market Overview
4.3 Serotonin Receptor Antagonist
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Serotonin Receptor Antagonist: Geographic Segmentation Analysis
4.4 Neurokinin NK1 Receptor Antagonist
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Neurokinin NK1 Receptor Antagonist: Geographic Segmentation Analysis
4.5 Dopamine Antagonist
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Dopamine Antagonist: Geographic Segmentation Analysis
4.6 Benzodiazepine
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Benzodiazepine: Geographic Segmentation Analysis
4.7 Other Segments).
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Other Segments).: Geographic Segmentation Analysis
Chapter 5: Chemotherapy-induced Nausea and Vomiting Drugs Market Application
5.1 Chemotherapy-induced Nausea and Vomiting Drugs Market Snapshot and Growth Engine
5.2 Chemotherapy-induced Nausea and Vomiting Drugs Market Overview
5.3
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 : Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Chemotherapy-induced Nausea and Vomiting Drugs Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ACACIA PHARMA GROUP PLC; APHIOS CORPORATION; BAXTER INTERNATIONAL INC.; DR. REDDY'S LABORATORIES LTD.; EISAI CO.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 LTD.; ESPECIFICOS STENDHAL S.A. DE C.V.; F. HOFFMANN-LA ROCHE AG; GLAXOSMITHKLINE PLC; HELSINN HEALTHCARE SA; HERON THERAPEUTICS
6.4 INC.; KYOWA HAKKO KIRIN CO.
6.5 LTD.; LEE'S PHARMACEUTICAL HOLDINGS LTD.; MERCK & CO.
6.6 INC.; MIDATECH PHARMA PLC; MUNDIPHARMA PTE.
6.7 LTD.; MYLAN N.V.; ONO PHARMACEUTICAL CO.
6.8 LTD.; OPKO HEALTH
6.9 INC.; ORCHID CHEMICALS & PHARMACEUTICALS LTD; OTSUKA PHARMACEUTICAL CO.
6.10 LTD.; PURDUE PHARMA LP; SANDOZ INTERNATIONAL GMBH; SCICLONE PHARMACEUTICALS
6.11 INC.; SHIN NIPPON BIOMEDICAL LABORATORIES LTD. (SNBL); SOLASIA PHARMA K.K.; SPECIALISED THERAPEUTICS ASIA PTE LTD; SUN PHARMACEUTICAL INDUSTRIES LTD.; TAIHO PHARMACEUTICAL CO.
6.12 LTD.; TESARO
6.13 INC.; TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 7: Global Chemotherapy-induced Nausea and Vomiting Drugs Market By Region
7.1 Overview
7.2. North America Chemotherapy-induced Nausea and Vomiting Drugs Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Serotonin Receptor Antagonist
7.2.2.2 Neurokinin NK1 Receptor Antagonist
7.2.2.3 Dopamine Antagonist
7.2.2.4 Benzodiazepine
7.2.2.5 Other Segments).
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Chemotherapy-induced Nausea and Vomiting Drugs Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Serotonin Receptor Antagonist
7.3.2.2 Neurokinin NK1 Receptor Antagonist
7.3.2.3 Dopamine Antagonist
7.3.2.4 Benzodiazepine
7.3.2.5 Other Segments).
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Chemotherapy-induced Nausea and Vomiting Drugs Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Serotonin Receptor Antagonist
7.4.2.2 Neurokinin NK1 Receptor Antagonist
7.4.2.3 Dopamine Antagonist
7.4.2.4 Benzodiazepine
7.4.2.5 Other Segments).
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Serotonin Receptor Antagonist
7.5.2.2 Neurokinin NK1 Receptor Antagonist
7.5.2.3 Dopamine Antagonist
7.5.2.4 Benzodiazepine
7.5.2.5 Other Segments).
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Chemotherapy-induced Nausea and Vomiting Drugs Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Serotonin Receptor Antagonist
7.6.2.2 Neurokinin NK1 Receptor Antagonist
7.6.2.3 Dopamine Antagonist
7.6.2.4 Benzodiazepine
7.6.2.5 Other Segments).
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Chemotherapy-induced Nausea and Vomiting Drugs Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Serotonin Receptor Antagonist
7.7.2.2 Neurokinin NK1 Receptor Antagonist
7.7.2.3 Dopamine Antagonist
7.7.2.4 Benzodiazepine
7.7.2.5 Other Segments).
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Chemotherapy-induced Nausea and Vomiting Drugs Scope:
|
Report Data
|
Chemotherapy-induced Nausea and Vomiting Drugs Market
|
|
Chemotherapy-induced Nausea and Vomiting Drugs Market Size in 2025
|
USD XX million
|
|
Chemotherapy-induced Nausea and Vomiting Drugs CAGR 2025 - 2032
|
XX%
|
|
Chemotherapy-induced Nausea and Vomiting Drugs Base Year
|
2024
|
|
Chemotherapy-induced Nausea and Vomiting Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Acacia Pharma Group Plc, Aphios Corporation, Baxter International Inc., Dr. Reddy's Laboratories Ltd., Eisai Co. Ltd., Especificos Stendhal S.A. DE C.V., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Helsinn Healthcare SA, Heron Therapeutics Inc., Kyowa Hakko Kirin Co. Ltd., Lee's Pharmaceutical Holdings Ltd., Merck & Co. Inc., Midatech Pharma PLC, Mundipharma Pte. Ltd., Mylan N.V., Ono Pharmaceutical Co. Ltd., Opko Health Inc., Orchid Chemicals & Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd., Purdue Pharma LP, Sandoz International GmbH, SciClone Pharmaceuticals Inc., Shin Nippon Biomedical Laboratories Ltd. (SNBL), Solasia Pharma K.K., Specialised Therapeutics Asia Pte Ltd, Sun Pharmaceutical Industries Ltd., Taiho Pharmaceutical Co. Ltd., Tesaro Inc., Teva Pharmaceutical Industries Ltd..
|
|
Key Segments
|
By Type
Serotonin Receptor Antagonist
Neurokinin NK1 Receptor Antagonist
Dopamine Antagonist
Benzodiazepine
Other Segments).
By Applications
|
